Hanseatic Management Services Inc Intra Cellular Therapies, Inc. Transaction History

Hanseatic Management Services Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$43.8 - $56.99 $436,773 - $568,304	9,972 New	9,972 $610,000
Q2 2022 Aug 05, 2022	BUY	$43.0 - $65.64 $10,621 - $16,213	247 Added 2.48%	10,219 $583,000
Q1 2022 Apr 29, 2022	BUY	$38.74 - $62.09 $386,315 - $619,161	9,972 New	9,972 $610,000
Q4 2018 Jan 29, 2019	SELL	$10.36 - $20.96 $435 - $880	-42 Closed	0 $0
Q3 2017 Nov 07, 2017	BUY	$10.77 - $22.1 $452 - $928	42	42 $1,000

381

84M

319K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $12B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Hanseatic Management Services Inc, based on Form 13F filings with the SEC.

Stay updated on Hanseatic Management Services Inc with notifications on news.